Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 336.76M |
| Revenue (ttm) | 6.62M |
| Net Income (ttm) | 145.20M |
| Shares Out | n/a |
| EPS (ttm) | 3.40 |
| PE Ratio | 2.32 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,153 |
| Average Volume | 18,589 |
| Open | 838.20 |
| Previous Close | 838.20 |
| Day's Range | 805.30 - 838.20 |
| 52-Week Range | 680.00 - 999.00 |
| Beta | 1.19 |
| RSI | 61.52 |
| Earnings Date | Nov 7, 2025 |
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. [Read more]
News
Oramed (ORMP) Implements Stockholder Rights Agreement
Oramed (ORMP) Implements Stockholder Rights Agreement
Oramed Pharmaceuticals GAAP EPS of $1.26
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) ...
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 20...
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partners...
Oramed Pharmaceuticals (ORMP) Receives $13 Million from Scilex for Warrants
Oramed Pharmaceuticals (ORMP) Receives $13 Million from Scilex for Warrants
Oramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical
Oramed Pharmaceuticals (ORMP) has closed a strategic investment in Alpha Tau Medical (DRTS). Through a registered direct offering, an affiliate of Oramed purcha
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials a...
Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of O...
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock
A February filing shows that Representative Brad Knott reported a sale in Oramed Pharmaceuticals (NASDAQ: ORMP), valued between $15,001 and $50,000. The transaction date is listed as February 25, 202...
Oramed announces spinoff of protein drug technology
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a dir...
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery pla...
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (...
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously ...
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to...
Oramed to Present at the 83rd American Diabetes Association Conference
NEW YORK , June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at...
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
NEW YORK , May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-per...
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK , May 15, 2023 /PRNewswire/ -- Oramed Pharmaceu...
Oramed Pharmaceuticals Issues Shareholder Update
NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from...
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or second...
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced ...
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...